Compass to submit psilocybin depression drug for approval imminently after stock wobbles
Compass Pathways expects to finalize a rolling submission for its highly anticipated psilocybin depression drug “in the next two weeks,”…
Compass Pathways expects to finalize a rolling submission for its highly anticipated psilocybin depression drug “in the next two weeks,”…